Role of gefitinib (G) in heavily pretreated non-small cell lung cancer (NSCLC)
| Autor: | Maximilian Papi, Emiliano Tamburini, Fabrizio Drudi, Carlotta Santelmo, Cinzia Castellani, Federica Carloni, E. Pasquini, Alberto Ravaioli, C. Possenti, Davide Tassinari |
|---|---|
| Rok vydání: | 2009 |
| Předmět: | |
| Zdroj: | Journal of Clinical Oncology. 27:e19102-e19102 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2009.27.15_suppl.e19102 |
| Popis: | e19102 Background: To assess the role of a palliative treatment with gefitinib in advanced and heavily pre-treated NSCLC. Methods: The records of all the consecutive patients treated with G in our department were reviewed; all the patients pre-treated with at least one courses of a platinum-containing regimen were considered eligible and enrolled into the trial. All the patients were treated with G 250 mg/die until progression of the disease or intractable toxicity. All the patients were evaluated every 21 days for toxicity and every 2 months for survival. Primary end point was time to progression (TTP); secondary ones were overall survival (OS) and safety. A sub-analysis comparing TTP and OS on the basis of sex (male/female), smoker status (smoker/never-smoker) and histology (adenocarcinoma/non-adenocarcinoma) was performed using the Log-Rank test. Results: Till today 63 patients were considered eligible and enrolled into the trial; the results are summarised in the table . Toxicity was mild with no haematological side effects, and no grade III-IV non-haematological toxicity. Conclusions: G seems to represent an interesting options in patients with NSCLC heavily pre-treated with chemotherapy. Our data seems to confirm that G is active mainly in female, no-smoker patients with adenocarcinoma, suggesting the need of reintroducing the molecule in the treatment of such a subset of patients. [Table: see text] No significant financial relationships to disclose. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|